Source briefingOctober 8, 2026Evidence
Draft guideline on the requirements for demonstrating therapeutic equivalence for nasal products
Source briefing · A concise briefing based on one linked source. It is intentionally shorter than a full FreedomWitness Evidence Engine analysis.
What the source reports
Draft guideline on the requirements for demonstrating therapeutic equivalence for nasal products
Evidence note: At this stage FreedomWitness is presenting what this source reports. This briefing does not independently prove every underlying claim and should be read together with the original material.
Source & verification
Primary source: What's new · October 8, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading
Genotype-informed docosahexaenoic acid dosing based on the FADS Indel to reduce preterm and prolonged gestation: A secondary analysis of the ADORE randomized trial
by Yan Ning Li, Kumar S. D. Kothapalli, Susan E. Carlson, Byron J. Gajewski, Emily A. DeFranco, J. Thomas Brenna Background Spontaneous early preterm…
Heart attack, stroke — and hip fractures
Endocrinologist discusses life-or-death stakes of weak bones and how to protect against devastating falls
Human medicines European public assessment report (EPAR): Hetronifly, serplulimab, Date of authorisation: 03/02/2025, Revision: 7, Status: Authorised
Human medicines European public assessment report (EPAR): Hetronifly, serplulimab, Date of authorisation: 03/02/2025, Revision: 7, Status: Authorised